Target Validation, Biomarker Discovery, and Patient Stratification

Understand the heterogenous nature of disease biology with an enhanced mechanistic understanding of pathology and interventions.
Translate your basic research findings in pathophysiology to discover new drug targets.
Discover novel disease biomarkers by taking a mechanistic approach to disease biology.

Validate which disease pathways are interrupted by your therapy. Perhaps more importantly - which are not. Discover new targets to grow your portfolio of assets.
Was a drug program a sunk cost for you? Find alternative therapeutic areas or sub-populations where your failed assets may be more effective.
Rank and compare ROI for your pipeline’s assets by probability of clinical success and gain leverage in your out licensing agreements.
Compare pathophysiology between target and off-target pathways.
Compare how your drug target compares with your competitors marketed in developing drugs.

Establish the most safe and effective dose for your expansion cohort/phase. Perform simulations to support your dosing rationale.
Predict off-target effects by evaluating your target’s overlap with other physiological pathways.
Predict pathways overlapping with those involved in standard of care therapies.
Simulate the effect of modulating multiple pathways simultaneously for your combination therapies.

Solutions at Every Phase of Drug Development

Understand more about your therapy’s mechanism of action than you ever thought possible by understand the causal mechanisms of efficacy.
Identify & validate new biomarkers as well as untangle correlative biomarkers from causal biomarkers.
Simulate protein concentrations to understand the extent to which protein concentrations are affected upstream/downstream of your target.

Discover which demographics and patient characteristics are co-variates.
Target the right population to reduce the number of patients required to meet efficacy endpoints.